文献速递妇科肿瘤

人乳头瘤病毒感染决定宫颈癌预后

Human Papillomavirus Infection Determines Prognosis in Cervical Cancer.
PubMed 文献 · J Clin Oncol · 2022-01-25

该研究对2845例侵袭性宫颈癌中392例聚合酶链反应阴性者行RNA测序,新检出169例HPV阳性,随访至2016年12月31日。高危HPV阳性组5年累积相对生存比为0.74,阴性组为0.45;阳性组超额死亡风险显著降低43%(超额风险比0.57,95%CI 0.48-0.69)。

要点

  • 高危HPV阳性组5年累积相对生存比为0.74(95%CI 0.72-0.75),阴性组为0.45(95%CI 0.39-0.51)。
  • 高危HPV阳性组较阴性组超额死亡风险降低43%(超额风险比0.57,95%CI 0.48-0.69)。
  • HPV风险组、进化支及感染数量与预后无关联。

核心结论

  • 高危HPV状态是宫颈癌诊断后15年以上预后的强决定因素,且独立于其他已知因素。

研究设计与样本

  • 对2845例侵袭性宫颈癌中392例聚合酶链反应HPV阴性者,在NovaSeq 6000平台行RNA测序,新检出169例HPV阳性。
  • 随访所有女性从诊断日期至2016年12月31日、移民或死亡(以先发生者为准),主要结局为截至2016年12月31日的全因死亡率。
  • 计算与女性一般人群比较的5年累积相对生存比,并用泊松回归估计肿瘤中13种最具致癌性(高危)HPV任一型感染的全因死亡率超额风险比。
  • 所有模型均校正年龄、诊断后时间、分期、组织学和教育水平。

主要发现

  • 高危HPV阴性组5年累积相对生存比为0.45(95%CI 0.39-0.51),高危HPV阳性组为0.74(95%CI 0.72-0.75)。
  • 高危HPV阳性组较阴性组超额死亡风险统计学显著降低43%(超额风险比0.57,95%CI 0.48-0.69)。
  • HPV风险组、进化支或HPV感染数量与预后无关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Detection of human papillomavirus (HPV) by polymerase chain reaction in invasive cervical cancer is strongly associated with prognosis but previous studies have not considered sequencing efforts. We aimed to assess the association when also including comprehensive analysis of HPV infection by deep sequencing and a longer follow-up period. MATERIALS AND METHODS: We subjected all 392 of 2,845 invasive cervical cancer cases that were polymerase chain reaction-negative for HPV to RNA sequencing on the NovaSeq 6000 platform (Illumina) and identified an additional 169 cases as HPV-positive. We followed all women from date of diagnosis to December 31, 2016, emigration, or death, whichever occurred first. The main outcome was all-cause mortality by December 31, 2016. We calculated 5-year cumulative relative survival ratios compared with the female general population and used Poisson regression to estimate excess hazard ratios of all-cause mortality by infection with any of the 13 most oncogenic (high-risk [hr]) HPV types in the tumor. All models were adjusted for age, time since diagnosis, stage, histology, and education level. RESULTS: The 5-year cumulative relative survival ratio was 0.45 (95% CI, 0.39 to 0.51) in the hrHPV-negative group, and 0.74 (95% CI, 0.72 to 0.75) in the hrHPV-positive group. This translated to a statistically significantly 43% lower excess mortality in the hrHPV-positive group compared with the hrHPV-negative (corresponding to an excess hazard ratio 0.57; 95% CI, 0.48 to 0.69). There was no association between HPV risk group, clade, or number of HPV infections and prognosis. CONCLUSION: hrHPV status is a strong determinant of cervical cancer prognosis over 15 years after diagnosis, above and beyond other established factors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lei J, Arroyo-Mühr LS, Lagheden C, et al. Human Papillomavirus Infection Determines Prognosis in Cervical Cancer. J Clin Oncol. 2022. PMID: 35077203. doi:10.1200/JCO.21.01930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。